Truxima dosage: Form, strength, how it’s given, and more

If you’ve been prescribed Truxima, your first thought might be: “Cool. What is it?” Your second thought is usually: “Okay… how much do I get, how often, and how long will I be attached to an IV pole like it’s my new coworker?” This guide walks through Truxima dosage in plain Englishits form and strength, how it’s given, the most common dosing schedules by condition, and the practical “what to expect” details that don’t always fit neatly on a pharmacy label.

Quick safety note: Truxima is a prescription biologic given by healthcare professionals. Your exact dose and schedule depend on your diagnosis, other medicines, lab results, and how you tolerate infusions. So use this article to understand the plannot to DIY one.

What is Truxima?

Truxima is a brand-name version of rituximab-abbs. It’s a monoclonal antibody (a targeted immune therapy) that attaches to a protein called CD20 found on certain B cells. By tagging those B cells, Truxima helps your immune system clear them out. That’s useful in several conditions where B cells play a starring role in the plotlike some blood cancers and autoimmune diseases.

Truxima is given by intravenous (IV) infusion, meaning it goes through a vein over a controlled period of time. You’ll get it in an infusion center, hospital, or clinic where staff can monitor you closely.

Dosage form and strengths

Truxima comes as a liquid solution in single-dose vials. The concentration is the same in both vial sizes: 10 mg per mL. What changes is the total amount of drug in the vial.

• 100 mg/10 mL (10 mg/mL) single-dose vial
• 500 mg/50 mL (10 mg/mL) single-dose vial

The vials are preservative-free, which is pharmacy-speak for “use what you need and discard the rest.” They’re stored refrigerated and protected from direct light. (No, your medication doesn’t want a tan.)

How Truxima is given

IV infusion only

Truxima is administered only as an IV infusion. It is not given as an IV push or bolus (a rapid injection). Infusions are done by trained healthcare professionals with appropriate medical support available, because infusion reactions can be serious.

Before the infusion: premeds (the “seatbelt” step)

Many patients receive medications before each infusion to reduce the chance and severity of infusion reactions. Premedication commonly includes:

• Acetaminophen (for fever/chills)
• An antihistamine (to calm allergy-type symptoms)
• A corticosteroid in certain conditions (often IV methylprednisolone), depending on your diagnosis and regimen

For some indications, your care team may also prescribe preventive medications against specific infections (for example, pneumonia prophylaxis in certain settings). This is individualized and based on your condition and risk factors.

During the infusion: standard infusion rates

Truxima infusions are typically started slowly and increased in steps if you tolerate them. This “start low, go slow” approach is designed to lower infusion-reaction riskespecially during the first infusion.

• First infusion (standard): often starts at 50 mg/hour, then increases by 50 mg/hour every 30 minutes if tolerated, up to 400 mg/hour.
• Subsequent infusions (standard): often start at 100 mg/hour, then increase by 100 mg/hour every 30 minutes if tolerated, up to 400 mg/hour.

If you have symptoms during the infusion (like chills, rash, shortness of breath, or blood pressure changes), the infusion may be slowed or temporarily stopped. When symptoms improve, it’s often restarted at a slower rate.

The 90-minute infusion option (for some patients)

In specific situationstypically certain previously untreated lymphoma patients receiving a glucocorticoid-containing chemotherapy regimensome people may qualify for a shorter infusion starting in a later cycle if they did not have severe infusion reactions in the first cycle and meet other clinical criteria.

The 90-minute approach is usually delivered as 20% of the total dose in the first 30 minutes, then the remaining 80% over the next 60 minutes. Not everyone is a candidate (for example, some cardiovascular conditions or certain lab findings may rule it out).

How doctors calculate your dose

Truxima dosing generally falls into two categories:

• Body-surface-area (BSA) dosing for many oncology indications (mg/m²). BSA is calculated using your height and weight.
• Fixed dosing (a set number of mg) for several autoimmune indications (for example, 1,000 mg on specific days).

A simple example of BSA dosing (for understanding only)

Suppose a lymphoma regimen uses 375 mg/m². If a patient’s BSA is 1.8 m², the calculated dose is: 375 × 1.8 = 675 mg. A pharmacy team then prepares that dose using available vial sizes and dilutes it into an infusion bag. Exact rounding and preparation rules vary by institution, so your infusion center will handle the math and mixing.

Truxima dosage by condition (common regimens)

The sections below describe typical dosing schedules used in FDA-approved labeling. Your clinician may tailor timing based on your response, side effects, and other treatments.

Non-Hodgkin’s lymphoma (NHL)

Truxima dosing for NHL is often 375 mg/m² per infusion, but the schedule changes based on the lymphoma subtype and whether Truxima is used alone, with chemotherapy, or as maintenance therapy.

• Relapsed or refractory, low-grade or follicular NHL (single-agent): commonly once weekly for several doses (often 4 or more depending on the regimen).
• Previously untreated follicular NHL (with chemotherapy): often given on Day 1 of each chemotherapy cycle for multiple cycles.
• Maintenance (selected follicular NHL settings): may be given every 8 weeks for a defined number of doses after response to initial therapy.
• Diffuse large B-cell lymphoma (DLBCL): typically given on Day 1 of each chemotherapy cycle, up to a set number of infusions.

Translation: the dose may look the same on paper (375 mg/m²), but your calendar can look wildly different depending on the treatment plan. Your oncology team will lay out a cycle-by-cycle roadmap.

Chronic lymphocytic leukemia (CLL)

In CLL, Truxima is commonly used with fludarabine and cyclophosphamide (often abbreviated “FC”). The dose may start lower in Cycle 1 and increase in later cycles.

• Cycle 1: often 375 mg/m²
• Cycles 2–6: often 500 mg/m²
• Schedule: typically aligned with 28-day cycles when used with FC

Because CLL and its treatments can affect immune function, your clinician may discuss infection prevention steps and monitoring plans before you start.

Rheumatoid arthritis (RA)

For RA, Truxima is given as a course (sometimes called a “cycle” or “round”), and it’s used in combination with methotrexate. A standard RA course is:

• 1,000 mg IV on Day 1
• 1,000 mg IV on Day 15 (two weeks later)

If additional treatment is needed, later courses are often given about every 24 weeks (around 6 months), based on clinical evaluation, and typically not sooner than about 16 weeks after the previous course.

Premedication with an IV corticosteroid (often methylprednisolone) 30 minutes prior to each infusion is commonly recommended in RA regimens to reduce infusion reactions.

Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA)

For these forms of ANCA-associated vasculitis, Truxima dosing is often described in two phases: induction (to control active disease) and follow-up/maintenance (to help keep disease controlled).

• Induction: commonly 375 mg/m² once weekly for 4 weeks, used with glucocorticoids.
• Follow-up/maintenance (after disease control): commonly 500 mg IV given as two infusions two weeks apart, then 500 mg IV every 6 months based on clinical evaluation.

Your vasculitis specialist may also recommend specific infection prophylaxis (for example, Pneumocystis pneumonia prevention) during treatment and for a defined period after, depending on your risk and regimen.

Pemphigus vulgaris (PV)

For pemphigus vulgaris, Truxima may be used with a tapering course of glucocorticoids. A common approach includes induction, maintenance, and relapse dosing:

• Induction: 1,000 mg IV on Day 1 and Day 15 (two infusions two weeks apart), with a tapering glucocorticoid course.
• Maintenance: 500 mg IV at Month 12 and then every 6 months thereafter, or based on clinical evaluation.
• Relapse: 1,000 mg IV at relapse, with clinician-guided steroid adjustments; subsequent infusions are typically spaced no sooner than 16 weeks.

Because PV treatment plans can vary, your dermatologist or specialist will tailor timing and supportive medications to your symptom pattern and steroid strategy.

As part of the Zevalin therapeutic regimen (certain NHL settings)

In specific cases, Truxima may be used as part of the Zevalin (ibritumomab tiuxetan) therapeutic regimen. The dose and timing are coordinated closely with Zevalin administration. This is a highly protocol-driven planyour oncology team will follow a regimen-specific schedule.

Preparation, dilution, and storage (the pharmacy side of the story)

Truxima is withdrawn from the vial and diluted into an infusion bag to a final concentration commonly in the range of 1 mg/mL to 4 mg/mL, using 0.9% sodium chloride or 5% dextrose. The bag is gently mixed (usually by inversionno vigorous shaking). Truxima is not typically mixed with other drugs in the same bag.

Diluted solutions may be refrigerated for a limited time and may remain stable for an additional period at room temperature, but because the product does not contain a preservative, clinics generally keep diluted infusions refrigerated when possible and follow institutional handling policies.

What if you miss an infusion?

Don’t try to “make up” a missed Truxima dose on your own (there is no safe home workaround for an IV infusion). If you miss an appointment, contact your clinic as soon as possible. They’ll reschedule you and adjust your calendar so you stay on track with the overall treatment plan.

Frequently asked questions

How long does a Truxima infusion take?

It depends on your regimen, infusion rate, and how you tolerate treatment. The first infusion is often the longest because it’s started slowly with step-up increases. Later infusions may be faster if you did well previously, and some patients in specific oncology settings may qualify for a 90-minute infusion schedule. Your clinic can usually estimate the time you’ll be there, including premeds, infusion, monitoring, and discharge steps.

Is Truxima dosing the same as rituximab (Rituxan)?

Truxima follows rituximab dosing frameworks in approved labeling, but your exact plan still depends on your condition, whether it’s combined with chemotherapy or methotrexate, and whether you’re in induction, maintenance, or retreatment. If you’re switching from another rituximab product, your clinician will map the schedule carefully.

Will my dose change over time?

In oncology, doses based on BSA can shift if your weight changes significantly. In autoimmune conditions, the dose is usually fixed, but the timing between courses may vary based on response, side effects, and lab monitoring. Infusion reactions can also lead to rate adjustments or supportive medication changes.

Bottom line

Truxima dosage isn’t “one-size-fits-all.” The medication comes in two single-dose vial strengths (100 mg/10 mL and 500 mg/50 mL), is given only by IV infusion, and has dosing schedules that depend heavily on the condition being treated. Oncology regimens often use 375 mg/m² (with schedule variations), while autoimmune regimens frequently use fixed 1,000 mg infusions two weeks apart, with later maintenance dosing in certain conditions.

The best move: ask your care team for a one-page infusion plan that lists the dates, dose, premeds, expected infusion time, and what symptoms should trigger a call. When you understand the “why” behind the schedule, the calendar becomes a lot less intimidating.

500-word experience section requested

Real-world experiences related to Truxima dosage (what people notice, day to day)

Beyond the official dosing charts, most patients care about one practical question: “What does this feel like in real life?” While everyone’s experience is different, there are a few common themes that show up across infusion centersespecially when it comes to how dosing is given and why the first infusion often feels like a bigger event than the ones that follow.

First, people are often surprised that “dose” doesn’t only mean “how many milligrams.” With Truxima, the rate is part of the experience. Many infusion centers start the first infusion slowly and increase in steps. Patients frequently describe the first visit as a “long appointment” rather than a “quick treatment,” partly because staff monitor closely for reactions. Some clinics encourage patients to treat it like a mini travel day: bring a phone charger, a sweater (infusion rooms can be chilly), snacks if allowed, and something to do that won’t require advanced calculus after an antihistamine.

Second, premedications are a big part of how people remember infusion day. Antihistamines can make some patients drowsy; acetaminophen can blunt fever/chills; and steroids used in certain regimens may leave others feeling wired, hungry, or wide awake later that night. This doesn’t mean something is wrongit’s often just the body’s reaction to the supportive meds. Patients who plan aheadlike arranging a ride home, keeping a light meal available, and not scheduling a big work presentation right afterwardoften report a smoother day. (Your immune therapy doesn’t care about your calendar invites, unfortunately.)

Third, people commonly notice that subsequent infusions can feel easier. If the first infusion goes well, later infusions may start at a higher rate or finish faster, depending on clinic protocol and your diagnosis. Many patients describe a “learning curve”: the first visit teaches them what to pack, how their body responds to premeds, and whether they prefer morning or afternoon appointments. The second and third visits tend to feel more routinestill important, but less mysterious.

Fourth, patients with body-surface-area dosing (common in oncology) sometimes find the math confusingespecially if the dose changes slightly after weight changes. A helpful mindset is to think of the pharmacy team as the “dose engineers.” They calculate the dose, choose the vial combination, dilute it properly, and document everything. Your job is not to calculate milligrams; your job is to show up, speak up about symptoms, and keep the team informed about side effects or infections between visits.

Finally, many patients say the most useful “experience tip” is learning what to report quickly. Infusion reactions can happen during the infusion or within 24 hours, and clinics typically give a symptom checklist. Patients often mention chills, itching, throat irritation, shortness of breath, rash, dizziness, or chest discomfort as “don’t wait on it” symptoms. It can feel awkward to hit the call button for something that might be minorbut infusion nurses would rather hear “this feels weird” early than manage a bigger reaction later. In other words: you are not being dramatic; you’re being medically efficient.

The overall theme people report is this: Truxima dosing is structured, monitored, and highly intentional. Once you understand that the schedule and infusion rate are designed to maximize benefit while minimizing risk, infusion day often feels less like a scary unknown and more like a well-run processwith you as the main character and the IV pole as your slightly clingy supporting actor.